4 completed, 2 withdrawn, 1 active not recruiting, 1 not yet recruiting. 8 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 4, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow imiglucerase: new trials by email Literature Review of imiglucerase trials Research Report on imiglucerase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3) Venglustat, Imiglucerase - Gaucher's Disease Type III | Phase 3 | Not yet recruiting | Sanofi | 18 | 2026-12-11 | 2026-11-10 |
| An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3 Gene therapy, Enzyme Replacement Agent - Gaucher Disease, Type 3 | Phase 2 / Phase 3 | Withdrawn | AVROBIO | 2023-10-01 | 2023-08-09 | |
| Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 Venglustat, imiglucerase - Gaucher's Disease Type III | Phase 3 | Active not recruiting | Sanofi | 43 | 2022-04-18 | 2026-07-13 |
| Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3 Eliglustat GZ385660, Imiglucerase GZ437843 - Gaucher's Disease Type I, Gaucher's Disease Type III | Phase 3 | Completed | Sanofi | 57 | 2018-04-11 | 2026-06-16 |
| Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease ISU302 - Gaucher Disease, Type 1 | Phase 3 | Completed | ISU Abxis Co., Ltd. | 8 | 2011-09-01 | 2017-07-12 |
| The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease Cerezyme®, ISU302 - Gaucher Disease | Phase 3 | Withdrawn | ISU Abxis Co., Ltd. | 2011-01-01 | 2016-08-23 | |
| A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE) Eliglustat tartrate, Imiglucerase - Gaucher Disease, Type 1 | Phase 3 | Completed | Genzyme, a Sanofi Company | 160 | 2009-09-01 | 2016-11-25 |
| Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease velaglucerase alfa, imiglucerase - Gaucher Disease, Type 1 | Phase 3 | Completed | Shire | 34 | 2008-01-29 | 2021-06-08 |
Gaucher Disease (8)
Sanofi (3) · ISU Abxis Co., Ltd. (2) · AVROBIO (1) · Genzyme, a Sanofi Company (1) · Shire (1)
Argentina (4) · United Kingdom (4) · Canada (3) · France (3) · Italy (3) · Russia (3) · Spain (3) · United States (3) · Germany (2) · Japan (2) · Turkey (Türkiye) (2) · Australia (1) · Brazil (1) · China (1) · Egypt (1)
Amel El Beshlawy, Prof. (1) · Milena Veselinovic, MD, PhD (1)
PMID 25819691, PMID 27839979, PMID 28167660
2008 (1), 2016 (1)